Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)
Stopped early · Phase 3 · Has a placebo group
Conditions studied: Pulmonary Disease, Chronic Obstructive
In brief
The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index/Transition Dyspnoea Index (BDI/TDI), the effect on health status as determined by the St George Respiratory Questionnaire (SGRQ) and the effect on chronic obstructive pulmonary disease (COPD) exacerbations.
Key facts
- Study ID
- NCT00662740
- Run by
- Boehringer Ingelheim
- People needed
- 220
- Starts
- 2008-04-15
- Expected to finish
- 2008-11-21
- Last updated by the study team
- 2023-08-23
Who can join
Age: 40 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- 1184.14.01018 Boehringer Ingelheim Investigational Site — Wheat Ridge, Colorado, United States
- 1184.14.01006 Boehringer Ingelheim Investigational Site — Winter Park, Florida, United States
- 1184.14.01003 Boehringer Ingelheim Investigational Site — Coeur d'Alene, Idaho, United States
- 1184.14.01015 Boehringer Ingelheim Investigational Site — South Bend, Indiana, United States
- 1184.14.01007 Boehringer Ingelheim Investigational Site — Lafayette, Louisiana, United States
- 1184.14.01005 Boehringer Ingelheim Investigational Site — Bangor, Maine, United States
- 1184.14.01020 Boehringer Ingelheim Investigational Site — Edina, Minnesota, United States
- 1184.14.01009 Boehringer Ingelheim Investigational Site — Burlington, North Carolina, United States
- 1184.14.01002 Boehringer Ingelheim Investigational Site — Cincinnati, Ohio, United States
- 1184.14.01021 Boehringer Ingelheim Investigational Site — Toledo, Ohio, United States
- 1184.14.01012 Boehringer Ingelheim Investigational Site — East Providence, Rhode Island, United States
- 1184.14.01017 Boehringer Ingelheim Investigational Site — Greenville, South Carolina, United States
- 1184.14.01008 Boehringer Ingelheim Investigational Site — Spartanburg, South Carolina, United States
- 1184.14.01014 Boehringer Ingelheim Investigational Site — Houston, Texas, United States
- 1184.14.01022 Boehringer Ingelheim Investigational Site — Killeen, Texas, United States
- 1184.14.01001 Boehringer Ingelheim Investigational Site — San Antonio, Texas, United States
- 1184.14.01010 Boehringer Ingelheim Investigational Site — Temple, Texas, United States
- 1184.14.01011 Boehringer Ingelheim Investigational Site — Richmond, Virginia, United States
- 1184.14.01019 Boehringer Ingelheim Investigational Site — Richmond, Virginia, United States
- 1184.14.43001 Boehringer Ingelheim Investigational Site — Feldbach, Austria
- 1184.14.32001 Boehringer Ingelheim Investigational Site — Brussels, Belgium
- 1184.14.32004 Boehringer Ingelheim Investigational Site — Turnhout, Belgium
- 1184.14.02005 Boehringer Ingelheim Investigational Site — Calgary, Alberta, Canada
- 1184.14.02003 Boehringer Ingelheim Investigational Site — Chilliwack, British Columbia, Canada
- 1184.14.01013 Boehringer Ingelheim Investigational Site — Boulder, Colorado, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.